Drug approval is the decision by a national or regional regulator that a medicine may be marketed for a specified use, based on an assessment that its benefits outweigh its risks for a defined patient population, that it can be manufactured to a consistent quality, and that its labelling accurately describes what is known about it.
Approval is therefore a judgement about a particular indication, population, dose, and formulation — not a general endorsement of a substance. The same molecule may be approved in one indication and refused in another, and approved in one jurisdiction while still under review in a second.
What Regulators Actually Assess
Efficacy
Does the medicine produce a clinically meaningful effect in the proposed indication? Regulators examine the design, conduct, and results of the clinical trials, focusing on the prespecified primary endpoint, the appropriateness of the comparator, the magnitude and consistency of effect, and whether the trial population resembles the population in the proposed labelling. Evidence based on surrogate endpoints receives closer scrutiny, since improvement in a marker does not guarantee patient benefit.
Safety
What harms occur, how often, how severe, and how manageable? Assessment covers the full safety database across the development programme, including adverse events, laboratory abnormalities, discontinuations, and deaths, together with signals from preclinical toxicology. The question is not whether harms exist — all effective medicines carry risk — but whether they are acceptable given the benefit and the seriousness of the condition.
Quality and Manufacturing
Can the product be made consistently to specification? Regulators review the manufacturing process, controls, stability data, impurity profiles, and facilities, which are subject to inspection under Good Manufacturing Practice. A product that cannot be manufactured reliably cannot be approved regardless of its clinical performance. This is particularly demanding for biologics and cell and gene therapies, where the process substantially defines the product.
Labelling and Risk Management
Does the proposed labelling accurately convey the indication, dosing, contraindications, warnings, and known adverse effects? Where risks require active management, regulators may require a formal risk management plan, restricted distribution, mandatory monitoring, or educational materials for prescribers and patients.
How the FDA Reviews a Medicine
A sponsor submits a New Drug Application for a small-molecule medicine or a Biologics License Application for a biologic. The application contains the complete clinical and non-clinical evidence, manufacturing information, and proposed labelling.
Review is conducted by multidisciplinary teams — clinical reviewers, statisticians, pharmacologists, chemists, and manufacturing specialists — who evaluate the submitted data, frequently reanalysing the underlying datasets rather than relying on the sponsor's analyses. The agency may convene an advisory committee of external experts, whose public discussion and vote inform but do not bind the decision. Inspections of clinical trial sites and manufacturing facilities may be conducted.
Outcomes include approval, approval with conditions such as post-marketing study requirements or a risk evaluation and mitigation strategy, or a complete response letter setting out the deficiencies preventing approval. Approval may be granted for a narrower indication than the sponsor sought.
How the EMA Reviews a Medicine
In the European Union, the centralised procedure allows a single application to cover all member states, and it is mandatory for certain categories including biotechnology-derived products, advanced therapies, orphan medicines, and products for defined serious conditions.
The application is assessed by the Committee for Medicinal Products for Human Use, supported by rapporteurs appointed from national agencies who lead the scientific evaluation, with input from specialist committees on safety, paediatric medicines, and advanced therapies. The committee issues a scientific opinion; the legally binding marketing authorisation is then granted by the European Commission and applies across the Union.
Alternative routes exist for products not requiring the centralised procedure, including national authorisation, mutual recognition, and decentralised procedures involving several member states.
How the Two Systems Differ
- Decision structure: the FDA both assesses and decides; in the EU the scientific opinion and the legal decision are separated between the EMA and the European Commission.
- Assessment model: the EMA coordinates a network drawing on national agency expertise; the FDA conducts review with in-house staff.
- Expert input: both use external advisory bodies, with differing procedures and degrees of public proceeding.
- Scope of the decision: an EU centralised authorisation covers all member states; separate national reimbursement decisions still determine funded access.
Both systems apply the same fundamental standard — demonstrated benefit-risk balance supported by adequate evidence — and outcomes usually converge, though differences in indication wording, population restrictions, and timing are common.
Expedited and Conditional Pathways
Both regulators operate mechanisms intended to bring treatments for serious conditions with unmet need to patients sooner.
In the United States these include fast track designation, breakthrough therapy designation, priority review, and accelerated approval, which permits authorisation based on a surrogate endpoint reasonably likely to predict clinical benefit, subject to confirmatory trials that must verify the benefit. If confirmation fails, procedures exist to withdraw the indication.
In the European Union, accelerated assessment shortens review timelines, conditional marketing authorisation permits approval on less comprehensive data with specific obligations to complete studies, authorisation under exceptional circumstances applies where comprehensive data cannot be generated, and the PRIME scheme provides enhanced early scientific support.
These pathways alter the sequence and timing of evidence generation. They do not remove the requirement for a favourable benefit-risk balance, and they typically create binding obligations to produce further evidence after authorisation.
Other Approval Routes
- Generic medicines are approved on the basis of bioequivalence to an approved reference product together with manufacturing quality, rather than repeating full clinical development.
- Biosimilars follow a tailored route demonstrating similarity to a reference biologic through analytical, functional, pharmacokinetic, and targeted clinical comparison.
- Orphan designations for rare diseases provide development incentives and, in some systems, extended market exclusivity, while still requiring evidence of benefit.
- Emergency and temporary authorisations allow use of unapproved products during declared public health emergencies under specific legal frameworks, with evidence requirements adapted to the circumstances and subject to review as data accumulate.
- Compassionate use and expanded access permit individual patients with serious conditions to receive investigational products outside trials, under defined conditions. These are not approvals.
After Approval
Regulatory involvement continues throughout a product's life. Pharmacovigilance systems collect adverse event reports from clinicians, patients, and manufacturers, and signal detection can identify harms that trials were too small or too short to reveal. Marketing authorisation holders are required to submit periodic safety reports and to notify regulators of new safety information.
Regulators can respond by updating the label, adding warnings or contraindications, restricting the indication or the prescribing setting, requiring additional studies, suspending the authorisation, or withdrawing the product. Manufacturing problems can trigger recalls independently of clinical safety concerns.
Approval Is Not Access
Authorisation permits marketing; it does not determine whether a health system pays for the medicine. Many countries operate separate health technology assessment and reimbursement processes that evaluate clinical and economic value and may fund a product only for a subgroup, or not at all. Clinical guidelines then position the product relative to alternatives. As a result, an approved medicine may be widely used in one country and effectively unavailable in another.
Sources
- U.S. Food and Drug Administration — drug approval process; New Drug Application; Biologics License Application; expedited programmes for serious conditions
- European Medicines Agency — centralised authorisation procedure; conditional marketing authorisation; PRIME; post-authorisation obligations
- European Commission — marketing authorisation decisions
- International Council for Harmonisation — Common Technical Document and efficacy, safety, quality guidelines
- World Health Organization — regulatory system strengthening and prequalification
